Malaria Vaccine Technology Roadmap update includes new targets
Read more »
Training and retaining young African scientists
By Dr. Margaret Gyapong, Director, Research Institution for Infectious Diseases of Poverty, based in Ghana
Read more »
Photo courtesy of PATH
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.
Rise in R&D funding could set stage for malaria eradication
Report hails recent progress in reducing malaria illnesses and deaths, but warns new tools are needed to fight parasite resistance.
Investment will go toward identifying novel targets of immunity and accelerate the development of malaria vaccines to support elimination and eradication.
PATH Malaria Vaccine Initiative names new director
Ashley Birkett, PhD, to lead key product development program at PATH.
Results from ongoing Phase III clinical trial announced
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children.
Modeling the public health impact of malaria vaccines for developers and policymakers
Paper in BMC Infectious Diseases describes a malaria vaccine model developed to address the specific needs of developers and policymakers.
ASTMH 62nd Annual Meeting
November 13–17, 2013
Twitter
Flickr